New Collaboration is Dedicated to Developing a Gene Therapy for Congenital Muscular Dystrophy

According to a story from globenewswire.com, the specialty pharmaceutical company Santhera Pharmaceuticals will be entering a collaborative partnership with the University of Basel's Biozentrum. The goal of this partnership will…

Continue Reading New Collaboration is Dedicated to Developing a Gene Therapy for Congenital Muscular Dystrophy

Saturday Afternoon Live: Dr. Steven Treon’s Presentation at the 2019 IWMF Educational Forum June 8th will be Streamed Online!

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) is a nonprofit organization founded by patients. Their mission? Support patients currently living with Waldenstrom's Macroglobulinemia (WM) while simultaneously supporting the search for a…

Continue Reading Saturday Afternoon Live: Dr. Steven Treon’s Presentation at the 2019 IWMF Educational Forum June 8th will be Streamed Online!

A Look at Progress in Healthcare and a Glimpse into the Future

  The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…

Continue Reading A Look at Progress in Healthcare and a Glimpse into the Future
Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
bdyczewski / Pixabay

Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…

Continue Reading Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

Finding Unbiased, Credible Information About Your Rare Disease Can Be Difficult, This Compilation of Resources May Help

When you or your child is first diagnosed with a rare disease it can be so difficult to know where to turn. You want to learn everything about the condition,…

Continue Reading Finding Unbiased, Credible Information About Your Rare Disease Can Be Difficult, This Compilation of Resources May Help
Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
cbd123 / Pixabay

Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD

According to a press release from the British biotechnology company GW Pharmaceuticals, the company has reported successful results at the conclusion of its phase 3 trial of tuberous sclerosis complex…

Continue Reading Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
Ireland’s HSE Faces Renewed Calls for Action Following NHS Deal for Critical Spinal Muscular Atrophy Drug
Free-Photos / Pixabay

Ireland’s HSE Faces Renewed Calls for Action Following NHS Deal for Critical Spinal Muscular Atrophy Drug

According to a story from thejournal.ie, Ireland's Health Services Executive (HSE) is facing renewed pressure from activists and patient advocates for a reasonable coverage decision regarding Spinraza, which is currently…

Continue Reading Ireland’s HSE Faces Renewed Calls for Action Following NHS Deal for Critical Spinal Muscular Atrophy Drug

Could This Revised Genetic Test Improve Diagnostic Rates for Familial Hypercholesterolemia?

According to a story from Healio, a recent study suggests that the addition of four more genes to the conventional genetic test used to diagnosed familial hypercholesterolemia could allow more…

Continue Reading Could This Revised Genetic Test Improve Diagnostic Rates for Familial Hypercholesterolemia?

Phase 3 Trial Results Continue to Show the Efficacy of Orencia as a Treatment for Juvenile Idiopathic Arthritis

Orencia Orencia (abatacept) is a treatment for juvenile idiopathic arthritis (JIA) that was approved for use in the U.S. for the pediatric patient population in 2008. In Japan, the therapy…

Continue Reading Phase 3 Trial Results Continue to Show the Efficacy of Orencia as a Treatment for Juvenile Idiopathic Arthritis
La NHS conclut un accord pour l’accès à un médicament essentiel contre l’atrophie musculaire spinale … pour le moment
PhotoLizM / Pixabay

La NHS conclut un accord pour l’accès à un médicament essentiel contre l’atrophie musculaire spinale … pour le moment

Selon un article de BBC News, le père Shakil Malji demande depuis des mois que sa jeune fille Maryam, atteinte d’une maladie rare et mortelle appelé l’atrophie musculaire spinale, puisse…

Continue Reading La NHS conclut un accord pour l’accès à un médicament essentiel contre l’atrophie musculaire spinale … pour le moment
England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
source: pixabay.com

England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen

According to a publication from Express Digest, Britain's National Health Service (NHS) has finally reached an agreement with American biotechnology company Biogen Inc. over the price of Spinraza - a…

Continue Reading England’s NHS Reaches Agreement for Coverage with SMA Drug Manufacturer Biogen
Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
stevepb / Pixabay

Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Poseida Therapeutics, Inc. recently announced that the company's investigational product candidate P-BCMA-101 has been granted Orphan Drug Designation from the US…

Continue Reading Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation